Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study
Priyatham (Prithu) S Mettu, MD
Updates from the Field
2019
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2022

Category: AMD-Non-Neovascular

See more